Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy.
Shakti Dhar ShuklaSteven L TaylorPeter G GibsonDaniel BarkerJohn W UphamIan A YangPaul N ReynoldsSandra HodgeAlan L JamesGeraint B RogersJodie L SimpsonPublished in: Thorax (2021)
Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1β and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced Haemophilus influenzae load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- cystic fibrosis
- allergic rhinitis
- end stage renal disease
- mycobacterium tuberculosis
- anti inflammatory
- randomized controlled trial
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- chronic kidney disease
- clinical trial
- machine learning
- electronic health record
- big data
- single molecule
- bone marrow
- cell therapy
- double blind